Administration of CD4 + CD25 high CD127 − FoxP3 + Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study

ConclusionsNo serious adverse events were reported in the 14 patients with MS treated with Treg cells in this study. The results suggest that IT administration is more promising than IV administration. Because of the low number of patients recruited, the statistical results may be underpowered and further studies are necessary to reach conclusions on efficacy and safety.Trial registrationEudraCT: 2014-004320-22; registered 18 November 2014.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research